Loading patent…
AssigneeFlagship Pioneering Innovations V, Inc.
InventorsBenjamin C. Blum, Alexis Benoit Hubaud, Peter Joseph Gough, Sabin Dhakal, Shreyas Jogidas Jadhav, Lauren Jessica Lahey, Erik Christian Hett, Christopher Ryan Shaler, Loren Matthew Brown, Xuqing Zhang, Yeon Sook Choi
Estimating the term…
In certain aspects, the disclosure relates to a nucleic acid molecule encoding one or more different thanotransmission polypeptides. Vectors (e.g., engineered viruses, plasmids and transposons), cells and pharmaceutical compositions comprising one or more nucleic acid molecules encoding one or more thanotransmission polypeptides are also disclosed. Methods of promoting thanotransmission by a target cell, methods of promoting an immune response in a subject, and methods of treating cancer in a subject are further disclosed.
A recombinant nucleic acid molecule comprising:
(canceled)
4-12. (canceled)
A recombinant nucleic acid molecule comprising:
14-16. (canceled)
18-28. (canceled)
(canceled)
34-35. (canceled)
38-41. (canceled)
43-45. (canceled)
47-48. (canceled)
50-51. (canceled)
The recombinant nucleic acid molecule of claim 9, wherein the 5′ UTR comprises SEQ ID NO:
53-64. (canceled)
66-68. (canceled)
70-77. (canceled)
A pharmaceutical composition comprising:
(canceled)
83-84. (canceled)
87-88. (canceled)
(canceled)
93-107. (canceled)
109-110. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.